Monthly Prescribing Reference

Cardamyst Approved for Self-Treatment of PSVT Episodes

Credit: Milestone Pharmaceuticals Cardamyst is supplied as a carton of 2 disposable nasal spray devices, each delivering 2 sprays containing a total of 70mg of etripamil. Cardamyst is expected to be ...
WGHP

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythm FDA approval in PSVT ...
NC Biotech

Charlotte’s Milestone Pharmaceuticals gains FDA approval for heart drug

Milestone Pharmaceuticals, a Canadian company with a U.S. subsidiary in Charlotte, is starting the new year with its first ...
WDAF-TV

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Analysis of data from 622 unique enrolled patients across multiple trials showed consistent efficacy of etripamil across multiple study phases, types of trial design, and geographic regions, with ...

Milestone Pharmaceuticals Announces Acceptance of Marketing Authorization Application for Etripamil Nasal Spray in PSVT by the European Medicines Agency

European decision on approval is expected by Q1 2027If approved, etripamil nasal spray is expected to offer patients a safe and effective ...
TipRanks on MSN

Milestone’s PSVT nasal spray MAA accepted by EMA

Milestone Pharmaceuticals ( ($MIST) ) has issued an announcement. On January 6, 2026, Milestone Pharmaceuticals announced that the European ...